GO
Loading...

Bristol-Myers Squibb Co

More

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of Johnson& Johnson's blood thinner, Xarelto, in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto in healthy volunteers aged 50-75 years.

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • NEW YORK, Jan 7- Halozyme Therapeutics Inc believes it has a multibillion-dollar cancer drug on its hands. Halozyme discussed interim data from a Phase II study of PEGPH20 with analysts and investors in New York on Wednesday, demonstrating its likelihood of delaying a worsening of the deadly cancer. "All that matters is that the tumor has to have a high...

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • FDA approves Bristol-Myer's skin cancer drug Monday, 22 Dec 2014 | 2:32 PM ET

    Dec 22- The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's drug for an advanced form of skin cancer. The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. The FDA's approval comes well before its scheduled review date of March 30.

  • Cramer Remix: Here’s what the Fed did Wednesday, 17 Dec 2014 | 7:06 PM ET
    Jim Cramer on Mad Money.

    The market may have rallied, but "Mad Money" host Jim Cramer thinks that’s just the beginning of Yellen’s impact.

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • NEW YORK, Dec 8- The U.S. government on Monday sued Deutsche Bank AG, seeking to recoup more than $190 million from the German bank over alleged tax fraud more than 14 years ago. According to a complaint filed in the U.S. District Court in Manhattan, Deutsche Bank used "insolvent" shell companies to conduct a series of fraudulent conveyances designed to hide taxable...

  • Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...

  • Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...

  • Cramer: Let's make money on marijuana Wednesday, 3 Dec 2014 | 6:50 PM ET

    Jim Cramer is ready to make money from marijuana, and thinks this stock could provide quite a buzz.

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • FDA declines to approve Bristol-Myers hepatitis drug Wednesday, 26 Nov 2014 | 11:56 AM ET

    Nov 26- Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

  • Early Movers: BHI, HAL, TSN, AGN, GM, MAR & more Monday, 17 Nov 2014 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.